Tuchelt H, Dekker K, Bähr V, Oelkers W
Division of Endocrinology, Department of Internal Medicine, Klinikum Benjamin Franklin, Freie Universität Berlin, Berlin, Germany.
Clin Endocrinol (Oxf). 2000 Sep;53(3):301-7. doi: 10.1046/j.1365-2265.2000.01089.x.
The insulin hypoglycaemia test (IHT) is believed to be the most reliable test for evaluating the entire hypothalamo-pituitary-adrenal (HPA) axis. The lower limit for the normal peak serum cortisol response has been reported to be between 500 and 580 nmol/l. Reference levels for a normal plasma ACTH response have not been reported recently.
We performed the IHT in 25 healthy subjects and in 109 patients with proven or suspected pituitary disorders with serial measurements of serum or plasma cortisol and of plasma ACTH, in order to establish reference levels and to study the dose-response relationship between ACTH and cortisol in this test. In most patients, other pituitary hormonal axes were evaluated in addition.
With the cortisol kit from Diagnostic Products Corporation (DPC), serum cortisol was about 13% lower than plasma (EDTA) levels with an excellent correlation between serum and plasma (r = 0.976; P<0.001). In the normals, the lower limit of the cortisol response (mean cortisol peak level minus 2 SD.) was 570 nmol/l for plasma and 500 nmol/l (calculated) for serum, while the lower limit of the ACTH response was 17.6 pmol/l (80 ng/l). In normals, the cortisol response was independent of the magnitude of the ACTH response. Seventeen out of 30 patients with ACTH responses to levels < 8.8 pmol/l (< 40 ng/l) had subnormal cortisol responses. However, 38 of the patients with pituitary disease had normal cortisol responses in spite of subnormal ACTH responses (group 2), while 47 patients had completely normal IHT results (group 1). Patients in group 2 had more often additional pituitary hormone deficiencies than those of group 1. The dose-response relationship between ACTH and cortisol in the patients resembled a dose-response curve that had been set up previously in normal subjects who received incremental doses of subcutaneous human ACTH (1-39).
The normal increment of plasma ACTH in the IHT is greater than necessary for stimulating serum cortisol to levels > 500 nmol/l. Patients with a subnormal ACTH but normal cortisol response in the IHT have a decreased ACTH secretory reserve. It is unlikely that they are at increased risk of developing an adrenal crisis perioperatively or in other stressful situations unless pituitary function deteriorates. The ACTH-cortisol relationship in the IHT performed in patients with pituitary disease shows no sharp dividing line between normality and disease, and whether a patient needs permanent glucocorticoid substitution is a discretionary decision.
胰岛素低血糖试验(IHT)被认为是评估整个下丘脑 - 垂体 - 肾上腺(HPA)轴最可靠的试验。据报道,正常血清皮质醇峰值反应的下限在500至580 nmol/L之间。最近尚未报道正常血浆促肾上腺皮质激素(ACTH)反应的参考水平。
我们对25名健康受试者和109名已证实或疑似垂体疾病的患者进行了IHT,连续测量血清或血浆皮质醇以及血浆ACTH,以建立参考水平并研究该试验中ACTH与皮质醇之间的剂量反应关系。在大多数患者中,还对其他垂体激素轴进行了评估。
使用诊断产品公司(DPC)的皮质醇检测试剂盒,血清皮质醇比血浆(乙二胺四乙酸)水平低约13%,血清与血浆之间具有良好的相关性(r = 0.976;P<0.001)。在正常人群中,血浆皮质醇反应的下限(平均皮质醇峰值水平减去2个标准差)为570 nmol/L,血清为500 nmol/L(计算值),而ACTH反应的下限为17.6 pmol/L(80 ng/L)。在正常人群中,皮质醇反应与ACTH反应的幅度无关。30名ACTH反应水平<8.8 pmol/L(<40 ng/L)的患者中有17名皮质醇反应低于正常水平。然而,38名垂体疾病患者尽管ACTH反应低于正常水平,但皮质醇反应正常(第2组),而47名患者的IHT结果完全正常(第1组)。第2组患者比第1组患者更常伴有其他垂体激素缺乏。患者中ACTH与皮质醇之间的剂量反应关系类似于先前在接受递增剂量皮下人ACTH(1 - 39)的正常受试者中建立的剂量反应曲线。
IHT中血浆ACTH的正常增量对于将血清皮质醇刺激至>500 nmol/L的水平来说是过大的。IHT中ACTH反应低于正常但皮质醇反应正常的患者,其ACTH分泌储备减少。除非垂体功能恶化,否则他们在围手术期或其他应激情况下发生肾上腺危象的风险不太可能增加。垂体疾病患者进行IHT时,ACTH与皮质醇之间的关系在正常与疾病之间没有明显的分界线,患者是否需要长期糖皮质激素替代是一个需要斟酌的决定。